(RGEN) Repligen - Ratings and Ratios
Protein,Ligands,Chromatography,Filtration,Analytics
RGEN EPS (Earnings per Share)
RGEN Revenue
Description: RGEN Repligen
Repligen Corporation is a life sciences company specializing in bioprocessing technologies and systems, operating globally across North America, Europe, the Asia Pacific, and other international regions. The company offers a diverse product portfolio, including Protein A ligands, cell culture growth factors, chromatography products, filtration systems, and process analytics solutions. These products cater to the needs of life sciences, biopharmaceutical, and diagnostics companies, as well as laboratory researchers and contract manufacturing organizations.
From a business perspective, Repligens products are crucial in the bioprocessing industry, particularly in the production of biologics. The companys chromatography products, such as OPUS pre-packed columns, and filtration systems, like XCell ATF Cell Retention Systems, play a vital role in the purification and processing of biologic drugs. Additionally, Repligens process analytics solutions, including SoloVPE and FlowVPE, enable customers to monitor and optimize their bioprocessing operations. The companys collaboration with Navigo Proteins GmbH to develop multiple affinity ligands further highlights its commitment to innovation and expanding its product offerings.
To evaluate Repligens performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses as a percentage of revenue can be considered. The companys revenue growth rate is a crucial metric, as it indicates the demand for its products and the companys ability to expand its customer base. A gross margin analysis can provide insights into Repligens pricing power and production efficiency. Furthermore, monitoring the companys operating expenses as a percentage of revenue can help assess its ability to manage costs and achieve profitability.
Other relevant KPIs for Repligen include its return on equity (ROE) and return on assets (ROA), which can be used to evaluate the companys profitability and asset utilization. Although the provided fundamental data indicates a negative ROE of -1.27, it is essential to analyze this metric over a longer period to understand the companys underlying trends. Additionally, Repligens forward price-to-earnings (P/E) ratio of 78.74 suggests that the market expects significant earnings growth in the future. By analyzing these KPIs and understanding the companys business dynamics, investors can make more informed decisions about Repligen Corporation.
RGEN Stock Overview
| Market Cap in USD | 6,677m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 1990-03-26 |
RGEN Stock Ratings
| Growth Rating | -74.1% |
| Fundamental | 40.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -31.4% |
| Analyst Rating | 4.26 of 5 |
RGEN Dividends
Currently no dividends paidRGEN Growth Ratios
| Growth Correlation 3m | -31% |
| Growth Correlation 12m | -67.2% |
| Growth Correlation 5y | -72.1% |
| CAGR 5y | -20.11% |
| CAGR/Max DD 3y | -0.39 |
| CAGR/Mean DD 3y | -0.68 |
| Sharpe Ratio 12m | -0.62 |
| Alpha | -43.31 |
| Beta | 0.966 |
| Volatility | 45.28% |
| Current Volume | 707.6k |
| Average Volume 20d | 671.3k |
| Stop Loss | 107.5 (-5.3%) |
| Signal | -2.02 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-13.8m TTM) > 0 and > 6% of Revenue (6% = 40.4m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -0.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 138.6% (prev 163.5%; Δ -24.90pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 132.1m > Net Income -13.8m (YES >=105%, WARN >=100%) |
| Net Debt (-22.8m) to EBITDA (135.6m) ratio: -0.17 <= 3.0 (WARN <= 3.5) |
| Current Ratio 8.59 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (56.5m) change vs 12m ago 0.13% (target <= -2.0% for YES) |
| Gross Margin 48.43% (prev 41.15%; Δ 7.28pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 23.39% (prev 21.05%; Δ 2.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.56 (EBITDA TTM 135.6m / Interest Expense TTM 22.4m) >= 6 (WARN >= 3) |
Altman Z'' 3.26
| (A) 0.32 = (Total Current Assets 1.06b - Total Current Liabilities 123.0m) / Total Assets 2.90b |
| (B) 0.15 = Retained Earnings (Balance) 428.1m / Total Assets 2.90b |
| (C) 0.02 = EBIT TTM 57.5m / Avg Total Assets 2.88b |
| (D) 0.51 = Book Value of Equity 426.9m / Total Liabilities 839.9m |
| Total Rating: 3.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 40.05
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 1.59% = 0.80 |
| 3. FCF Margin 15.40% = 3.85 |
| 4. Debt/Equity 0.27 = 2.46 |
| 5. Debt/Ebitda 4.06 = -2.50 |
| 6. ROIC - WACC -7.06% = -8.82 |
| 7. RoE -0.69% = -0.11 |
| 8. Rev. Trend -29.71% = -1.49 |
| 9. Rev. CAGR -3.43% = -0.57 |
| 10. EPS Trend -62.77% = -1.57 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of RGEN shares?
Over the past week, the price has changed by -5.93%, over one month by -10.34%, over three months by -9.95% and over the past year by -18.90%.
Is Repligen a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RGEN is around 87.15 USD . This means that RGEN is currently overvalued and has a potential downside of -23.24%.
Is RGEN a buy, sell or hold?
- Strong Buy: 10
- Buy: 4
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RGEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 179.8 | 58.3% |
| Analysts Target Price | 179.8 | 58.3% |
| ValueRay Target Price | 97.5 | -14.1% |
Last update: 2025-09-11 04:48
RGEN Fundamental Data Overview
CCE Cash And Equivalents = 708.9m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 57.4713
P/S = 9.9075
P/B = 3.2386
P/EG = 2.59
Beta = 1.072
Revenue TTM = 674.0m USD
EBIT TTM = 57.5m USD
EBITDA TTM = 135.6m USD
Long Term Debt = 533.7m USD (from longTermDebt, last quarter)
Short Term Debt = 16.0m USD (from shortTermDebt, last quarter)
Debt = 549.8m USD (Calculated: Short Term 16.0m + Long Term 533.7m)
Net Debt = -22.8m USD (from netDebt column, last quarter)
Enterprise Value = 6.52b USD (6.68b + Debt 549.8m - CCE 708.9m)
Interest Coverage Ratio = 2.56 (Ebit TTM 57.5m / Interest Expense TTM 22.4m)
FCF Yield = 1.59% (FCF TTM 103.8m / Enterprise Value 6.52b)
FCF Margin = 15.40% (FCF TTM 103.8m / Revenue TTM 674.0m)
Net Margin = -2.05% (Net Income TTM -13.8m / Revenue TTM 674.0m)
Gross Margin = 48.43% ((Revenue TTM 674.0m - Cost of Revenue TTM 347.5m) / Revenue TTM)
Tobins Q-Ratio = 15.27 (Enterprise Value 6.52b / Book Value Of Equity 426.9m)
Interest Expense / Debt = 1.05% (Interest Expense 5.77m / Debt 549.8m)
Taxrate = 18.39% (3.35m / 18.2m)
NOPAT = 46.9m (EBIT 57.5m * (1 - 18.39%))
Current Ratio = 8.59 (Total Current Assets 1.06b / Total Current Liabilities 123.0m)
Debt / Equity = 0.27 (Debt 549.8m / last Quarter total Stockholder Equity 2.06b)
Debt / EBITDA = 4.06 (Net Debt -22.8m / EBITDA 135.6m)
Debt / FCF = 5.30 (Debt 549.8m / FCF TTM 103.8m)
Total Stockholder Equity = 2.01b (last 4 quarters mean)
RoA = -0.48% (Net Income -13.8m, Total Assets 2.90b )
RoE = -0.69% (Net Income TTM -13.8m / Total Stockholder Equity 2.01b)
RoCE = 2.26% (Ebit 57.5m / (Equity 2.01b + L.T.Debt 533.7m))
RoIC = 1.85% (NOPAT 46.9m / Invested Capital 2.54b)
WACC = 8.91% (E(6.68b)/V(7.23b) * Re(9.57%)) + (D(549.8m)/V(7.23b) * Rd(1.05%) * (1-Tc(0.18)))
Shares Correlation 3-Years: -53.44 | Cagr: -0.13%
Discount Rate = 9.57% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.64% ; FCFE base≈110.0m ; Y1≈135.7m ; Y5≈231.5m
Fair Price DCF = 53.30 (DCF Value 3.00b / Shares Outstanding 56.3m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: -29.71 | Revenue CAGR: -3.43%
Rev Growth-of-Growth: 28.49
EPS Correlation: -62.77 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 155.4
Additional Sources for RGEN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle